Summaries & Highlights
2024 ESMO Annual Meeting Insights Hub
ESMO Asia 2024 Summary: mUC Key Trial Analysis - KEYNOTE-A39, CheckMate 901, SPADE, and TROPiCS-04
FEATURING
Terence Friedlander
- December 17, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Long-Term Survival Outcomes in Advanced Melanoma - Insights From CheckMate 067, KEYNOTE-006, and ImmunoCobiVem Trials
FEATURING
Jessica Hassel
- 34 views
- November 6, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimal Sequencing of Therapeutic Strategies in Immunogenic mCRC
FEATURING
Thierry André
- 53 views
- November 5, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Sequencing CRC Targeted Therapies Based on Biomarkers and Biology
FEATURING
Lukas Weiss
- 65 views
- November 4, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Developmental Therapeutics Highlights
FEATURING
Guru Sonpavde
- 268 views
- October 25, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Breast12, CAPItello-290, and ICARUS-BREAST01
FEATURING
Sara Tolaney,
Hope Rugo
- 556 views
- October 4, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges
FEATURING
Mansoor Raza Mirza
- 375 views
- September 20, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in HCC
FEATURING
Richard Kim,
Tiago Biachi
- 222 views
- October 21, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancreatic Cancer
FEATURING
Davide Melisi
- 253 views
- October 17, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer
FEATURING
Jens Huober
- 352 views
- October 17, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE
FEATURING
Sara Tolaney,
Hope Rugo
- 586 views
- October 4, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Shaping Prostate Cancer Trials
FEATURING
Eleni Efstathiou
- 102 views
- October 15, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Practice
FEATURING
Hani Babiker
- 326 views
- October 14, 2024
- 5
ecancer
ESMO 2024 Insights: ROME Basket Trial - Targeting Actionable Mutations vs. SoC in Pts With Advanced Solid Tumors
FEATURING
Andrea Botticelli
- 15 views
- October 22, 2024
ecancer
ESMO 2024 Summary: Highlights & Analysis of the Biggest Solid Cancer Updates
FEATURING
Bishal Gyawali
- 43 views
- October 21, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01
FEATURING
Paolo Tarantino
- 842 views
- September 24, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in CRC and Impacts on Practice
FEATURING
Richard Kim,
Tiago Biachi
- 230 views
- October 21, 2024
- 4
ecancer
ESMO 2024: Optimizing the Personalization of Prostate Cancer Treatment
- 48 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in HCC and Impacts on Practice
FEATURING
Hani Babiker
- 170 views
- October 14, 2024
- 1
ecancer
ESMO 2024 Summary: Understanding the Use of PARPi Combinations to Treat Patients With mCRPC
- 23 views
- October 11, 2024
ecancer
ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr
- 260 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)
FEATURING
Robert Dreicer
- 340 views
- September 24, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 469 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
FEATURING
Lorenza Rimassa
- 405 views
- September 20, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR
FEATURING
Petros Grivas
- 255 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Highlights
FEATURING
Nabil Saba
- 337 views
- September 23, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder and RCC Highlights
FEATURING
Karine Tawagi,
Natalie Reizine
- 113 views
- October 10, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights of Radioligand Therapies in Prostate Cancer
FEATURING
Natalie Reizine,
Karine Tawagi
- 79 views
- October 10, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients With Bone Metastases
FEATURING
Robbe Van den Begin
- 462 views
- September 26, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights of Important Trials in Sarcoma
FEATURING
Robin Jones
- 213 views
- October 9, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Neoadjuvant Immunotherapy as the Future of Melanoma Treatment - Identifying Patients Who Need Surgery
FEATURING
Alexander van Akkooi
- 63 views
- October 9, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Novel Agents and Promising Combinations in mRCC and mUC
FEATURING
Begoña Pérez-Valderrama
- 64 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Managing Durable Responses and De-Escalation Strategies in Urothelial Cancer With Systemic Therapy
FEATURING
Debbie Robbrecht
- 24 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond
FEATURING
Lisa Carey
- 371 views
- October 8, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in the Treatment of MCL
FEATURING
Georg Hess
- 240 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New Therapeutic Approaches in Gynecologic Cancers
FEATURING
Susana Banerjee
- 91 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Take Home Messages
FEATURING
Paolo Bossi
- 365 views
- October 8, 2024
- 6
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Discussing Key Studies on the Use of Zipalertinib, Zidesamtinib, and PM8002/BNT327 With CT in NSCLC
FEATURING
Joop Langen
- 77 views
- October 7, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimizing Precision Therapy in HR+/HER2- Advanced Breast Cancer Post-Endocrine + CDK4/6i
FEATURING
Philippe Aftimos
- 194 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Liquid Biopsies in GI Cancers - Learnings From Colorectal Cancer
FEATURING
Naureen Starling
- 190 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clinical and Translational Advances
FEATURING
Julien Taieb
- 343 views
- October 6, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predicting the Outcomes of Advanced Cutaneous Melanoma Cases Following Discontinuation of Immune Checkpoint Inhibition
FEATURING
Ka-Won Noh,
Oana Diana Persa
- 70 views
- October 3, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimizing Curative Opportunities in Early HCC
FEATURING
Stephen L. Chan
- 109 views
- October 2, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC), and CheckMate 9ER (aRCC)
FEATURING
Camillo Porta
- 185 views
- October 2, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Evaluation of Ivonescimab + CT and PM8002/BNT327 + Nab-Paclitaxel for 1L TNBC: Results From Two Studies
FEATURING
Carmen Criscitiello
- 166 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Metastatic Melanoma Highlights
FEATURING
Christian Blank
- 211 views
- September 25, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose
FEATURING
Howard Hochster
- 484 views
- September 23, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and Other Updates
FEATURING
Elizabeth R. Plimack
- 181 views
- September 27, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in mBC
FEATURING
Giampaolo Bianchini
- 533 views
- October 1, 2024
- 8
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - AURORA Program, DAISY Trial, DESTINY-Breast06 Study, and Targeted Therapy Sequencing
FEATURING
Christos Sotiriou
- 543 views
- October 1, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated Cholangiocarcinoma - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 41 views
- September 30, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Primary CNS Lymphoma - Updated ESMO and EHA Guidelines
FEATURING
Andres Ferreri
- 99 views
- September 30, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC
FEATURING
Michail Ignatiadis
- 151 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
FEATURING
Virginia Kaklamani
- 539 views
- September 23, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 158 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease
FEATURING
Domenica Lorusso
- 205 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials
FEATURING
Douglas Johnson
- 195 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC
FEATURING
Félix Guerrero-Ramos
- 56 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4
FEATURING
Bogdana Schmidt
- 124 views
- September 23, 2024
- 2
Breast
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Sacituzumab Govitecan in Previously Treated mTNBC
FEATURING
Adam Brufsky
- 14 views
- November 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-Year Outcomes From the NATALEE Trial
FEATURING
Peter Fasching
- 70 views
- November 19, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Residual Cancer Burden & Adjuvant Capecitabine in Early TNBC With Non-pCR
FEATURING
Sung-Bae Kim
- 69 views
- November 15, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TroFuse-010 Trial - Sacituzumab Tirumotecan ± Pembro vs. Chemo in HR+/HER2- Advanced BC
FEATURING
Sara Tolaney
- 262 views
- November 4, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Long-Term Outcomes and Treatment Strategies by ER Expression in Breast Cancer
FEATURING
Kazuki Nozawa
- 113 views
- October 29, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Outcomes in HR+/HER2- eBC by Prior Systemic Therapy - Insights From the NATALEE Trial Subgroup Analysis
FEATURING
Nicholas McAndrew
- 219 views
- October 25, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE
FEATURING
Sara Tolaney,
Hope Rugo
- 586 views
- October 4, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: mBC Panel Discussion on Key Studies - DESTINY-Breast12, CAPItello-290, and ICARUS-BREAST01
FEATURING
Sara Tolaney,
Hope Rugo
- 556 views
- October 4, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
FEATURING
Virginia Kaklamani
- 539 views
- September 23, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01
FEATURING
Paolo Tarantino
- 842 views
- September 24, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - AURORA Program, DAISY Trial, DESTINY-Breast06 Study, and Targeted Therapy Sequencing
FEATURING
Christos Sotiriou
- 543 views
- October 1, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Tailoring Therapy in TNBC and Beyond
FEATURING
Lisa Carey
- 371 views
- October 8, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in mBC
FEATURING
Giampaolo Bianchini
- 533 views
- October 1, 2024
- 8
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Systemic Treatment for ILCs in Breast Cancer
FEATURING
Jens Huober
- 352 views
- October 17, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimizing Precision Therapy in HR+/HER2- Advanced Breast Cancer Post-Endocrine + CDK4/6i
FEATURING
Philippe Aftimos
- 194 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC
FEATURING
Michail Ignatiadis
- 151 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Evaluation of Ivonescimab + CT and PM8002/BNT327 + Nab-Paclitaxel for 1L TNBC: Results From Two Studies
FEATURING
Carmen Criscitiello
- 166 views
- October 1, 2024
ecancer
ESMO 2024 Insights: Neo-CheckRay Trial - Durvalumab & Oleclumab Boost for SBRT + Chemo in ER+/HER2- eBC
FEATURING
Alex De Caluwe
- 16 views
- October 11, 2024
ecancer
ESMO 2024 Insights: WSG-TP-II Trial - ET + Trastuzumab & Pertuzumab vs. De-Escalated Chemo + Trastuzumab & Pertuzumab in HR+/HER2+ eBC
FEATURING
Oleg Gluz
- 43 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- and Node+ HR+/HER2- eBC From US Electronic Health Records
FEATURING
Komal Jhaveri
- 231 views
- October 17, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Ovarian Function Suppression in HR+ HER2+ Breast Cancer - Exploratory Analysis From HERA Trial
FEATURING
Sung Gwe Ahn
- 44 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: T-DXd in HER2+ mBC With or Without Brain Metastases - DESTINYBreast-12 Primary Results
FEATURING
Nancy Lin
- 214 views
- October 8, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Breast04 - Exploratory Biomarker Analysis of T-DXd vs. Physician’s Choice in HR+/HER2- mBC
FEATURING
Naoto Ueno
- 262 views
- October 9, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: A Registry-Based Study of pCR & Survival After Neoadjuvant Chemo in Stage I TNBC
FEATURING
Manon De Graaf
- 47 views
- October 1, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TRIPLE-B Study - 1L Carboplatin-Cyclophosphamide vs. Paclitaxel +/- Atezolizumab for mTNBC
FEATURING
Rosie Voorthuis
- 56 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Quantitative High Sensitivity HER2 Testing With Trastuzumab Deruxtecan in mBC
FEATURING
Paolo Tarantino
- 259 views
- October 1, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarchE Eligible Populations - A US Electronic Health Records Analysis
FEATURING
Paolo Tarantino
- 221 views
- September 27, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC
FEATURING
Giuseppe Viale
- 363 views
- September 23, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CAPItello-290 Trial - Capivasertib + Paclitaxel as 1L Treatment for mTNBC
FEATURING
Heather McArthur
- 140 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo + CT in High-Risk Early TNBC - OS Results From KEYNOTE-522
FEATURING
Heather McArthur
- 157 views
- September 24, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Prognostic Role of TILs on OS and Treatment De-Escalation in HER2+ Early BC in the ShortHER Trial
FEATURING
Maria Vittoria Dieci
- 108 views
- September 19, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DETECT V trial - Omission of Chemo and Addition of the CDK4/6i Ribociclib in HER2+ and HR+ mBC
FEATURING
Wolfgang Janni
- 31 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PROMENADE Trial - Pembro for Early ER-Low/HER2- BC - Real World French Cohort
FEATURING
Francois Cherifi
- 89 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Hypo vs. Normofractionated RT in eBC - 5-Year Results of HypoG-01
FEATURING
Sofia Rivera
- 165 views
- September 20, 2024
- 1
GI
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: IMHOTEP Trial - Neo-Adjuvant IO for dMMR/MSI CRC
FEATURING
Olivier Dubreuil
- 36 views
- November 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Efficacy of 177Lu-DOTA-TATE in GEP-NETs - Multivariate Analysis of NETTER-2 Study
FEATURING
Diego Ferone
- 37 views
- November 13, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimal Sequencing of Therapeutic Strategies in Immunogenic mCRC
FEATURING
Thierry André
- 53 views
- November 5, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Sequencing CRC Targeted Therapies Based on Biomarkers and Biology
FEATURING
Lukas Weiss
- 65 views
- November 4, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose
FEATURING
Howard Hochster
- 484 views
- September 23, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clinical and Translational Advances
FEATURING
Julien Taieb
- 343 views
- October 6, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
FEATURING
Lorenza Rimassa
- 405 views
- September 20, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in HCC
FEATURING
Richard Kim,
Tiago Biachi
- 222 views
- October 21, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in CRC and Impacts on Practice
FEATURING
Richard Kim,
Tiago Biachi
- 230 views
- October 21, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancreatic Cancer
FEATURING
Davide Melisi
- 253 views
- October 17, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Practice
FEATURING
Hani Babiker
- 326 views
- October 14, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in HCC and Impacts on Practice
FEATURING
Hani Babiker
- 170 views
- October 14, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Liquid Biopsies in GI Cancers - Learnings From Colorectal Cancer
FEATURING
Naureen Starling
- 190 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Optimizing Curative Opportunities in Early HCC
FEATURING
Stephen L. Chan
- 109 views
- October 2, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cancer - Nature vs. Nurture
FEATURING
Shuji Ogino
- 348 views
- October 1, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated AML - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 55 views
- September 30, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid Syndrome
FEATURING
Rachel Riechelmann
- 106 views
- September 24, 2024
- 3
ecancer
ESMO 2024 Insights: NO-CUT Trial - Total Neoadjuvant Treatment Without Surgery for Locally Advanced Rectal Cancer
FEATURING
Alessio Amatu
- 184 views
- October 14, 2024
- 1
ecancer
ESMO 2024 Insights: ROME Basket Trial - Targeting Actionable Mutations vs. SoC in Pts With Advanced Solid Tumors
FEATURING
Andrea Botticelli
- 15 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs. Len or Sorafenib in 1L Unresectable HCC
FEATURING
Hatim Karachiwala
- 136 views
- October 21, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Machine Learning-Based Prediction of Lymph Node Metastasis in Early Gastric Cancer
FEATURING
Weiyao Li
- 15 views
- October 21, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: The Value of Immune Checkpoint Blockade in MSS/pMMR mCRC
FEATURING
Benjamin Geisler
- 133 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EPOC2001 Study - Lenvatinib + Pembro + FLOT in Neoadjuvant/Adjuvant Treatment for Gastric and GEJ Adenocarcinoma
FEATURING
Akihito Kawazoe
- 155 views
- October 3, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Gastric03 - T-DXd Monotherapy and Combinations in Pts With Adv/Metastatic HER2+ Esophageal, Gastric, or GEJ Adenocarcinoma
FEATURING
Yelena Janjigian
- 139 views
- October 2, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC
FEATURING
Lorenza Rimassa
- 173 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study
FEATURING
David Tougeron
- 63 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Fruquintinib in Refractory mCRC - Subgroup Analysis of the FRESCO-2 Trial
FEATURING
Rocio Garcia-Carbonero
- 59 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma
FEATURING
Sheela Rao
- 70 views
- September 27, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro + CAPOX + Bevacizumab in MSS mCRC With High Immune Infiltrate - FFCD 1703 POCHI Trial
FEATURING
David Tougeron
- 84 views
- September 27, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - Ph3 LEAP-012 Study
FEATURING
Josep Llovet
- 210 views
- September 23, 2024
- 3
GU
2024 ESMO Annual Meeting Insights Hub
ESMO Asia 2024 Summary: mUC Key Trial Analysis - KEYNOTE-A39, CheckMate 901, SPADE, and TROPiCS-04
FEATURING
Terence Friedlander
- December 17, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Developmental Therapeutics Highlights
FEATURING
Guru Sonpavde
- 268 views
- October 25, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR
FEATURING
Petros Grivas
- 255 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and Other Updates
FEATURING
Elizabeth R. Plimack
- 181 views
- September 27, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 158 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)
FEATURING
Robert Dreicer
- 340 views
- September 24, 2024
- 4
ecancer
ESMO 2024: Optimizing the Personalization of Prostate Cancer Treatment
- 48 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Shaping Prostate Cancer Trials
FEATURING
Eleni Efstathiou
- 102 views
- October 15, 2024
ecancer
ESMO 2024 Summary: Understanding the Use of PARPi Combinations to Treat Patients With mCRPC
- 23 views
- October 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder and RCC Highlights
FEATURING
Karine Tawagi,
Natalie Reizine
- 113 views
- October 10, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4
FEATURING
Bogdana Schmidt
- 124 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC
FEATURING
Félix Guerrero-Ramos
- 56 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC), and CheckMate 9ER (aRCC)
FEATURING
Camillo Porta
- 185 views
- October 2, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights of Radioligand Therapies in Prostate Cancer
FEATURING
Natalie Reizine,
Karine Tawagi
- 79 views
- October 10, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Novel Agents and Promising Combinations in mRCC and mUC
FEATURING
Begoña Pérez-Valderrama
- 64 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Managing Durable Responses and De-Escalation Strategies in Urothelial Cancer With Systemic Therapy
FEATURING
Debbie Robbrecht
- 24 views
- October 8, 2024
ecancer
ESMO 2024 Insights: PEACE-3 Trial - Enzalutamide Treatment Boosted by Radium-223 in mCRPC
FEATURING
Silke Gillessen
- 57 views
- October 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SWOG-1216 Trial - Inherited Variants in SRD5A Genes & Response to Hormonal Therapy in Prostate Cancer
FEATURING
Jacek Pinski
- 32 views
- October 11, 2024
ecancer
ESMO 2024 Insights: SUNNIFORECAST Trial - Nivo + Ipi vs. Standard of Care in Non-Clear-Cell RCCs
FEATURING
Lothar Bergmann
- 10 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Baseline Radiological Tumor Burden and Outcomes in mccRCC Treated With 1L IO-Based Regimens
FEATURING
Rashad Nawfal
- 14 views
- October 17, 2024
ecancer
ESMO 2024 Insights: JCOG1019 Study - Watchful Waiting vs. Intravesical BCG in HGT1 Bladder Cancer
FEATURING
Hiroshi Kitamura
- 41 views
- October 16, 2024
- 1
ecancer
ESMO 2024 Insights: Best Practice in HRRm Testing in Patients With Metastatic Prostate Cancer
- 93 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Circulating Tumor Cell Enumeration and OS in mCRPC Treated With Xaluritamig
FEATURING
Andrew Armstrong
- 33 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Glycoproteomic Biomarkers as Predictors of NIVO+CABO vs. Sunitinib Response in aRCC - CheckMate 9ER
FEATURING
David Braun
- 83 views
- October 17, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Safety & Activity of First-in-Class Dual AR Degrader & Antagonist BMS-986365 in Heavily Pretreated mCRPC Patients
FEATURING
Andrew Armstrong
- 24 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: 1L EV + Pembro in Cis-Ineligible la/mUC - 5-Year Follow-Up of Study EV-103 DE/A
FEATURING
Jonathan Rosenberg
- 46 views
- October 10, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: JCOG1019 Phase 3 Study Comparing the Effectiveness of Watchful Waiting & Intravesical BCG in Pts With HGT1 Bladder Cancer With pT0 on the 2nd Transurethral Resection Specimen
FEATURING
Hiroshi Kitamura
- 4 views
- October 10, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Futibatinib + Pembro in Advanced/Metastatic Urothelial Carcinoma - Final Analysis of Efficacy and Safety
FEATURING
Vadim Koshkin
- 80 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Response Evaluation Using ctDNA and PET Imaging in mCRPC Treated With LuPSMA + Pembro - PRINCE Trial
FEATURING
Sofie Tolmeijer
- 110 views
- October 4, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan vs. Everolimus in Patients With Previously Treated Advanced ccRCC
FEATURING
Brian Rini
- 99 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Comparison P - Upfront Accelerated 177Lu-PSMA-617 in mHSPC
FEATURING
Minal Padden-Modi,
Nick James
- 68 views
- September 25, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation vs. Placebo in Patients Receiving Pembro + Axitinib for mRCC
FEATURING
Chiara Ciccarese
- 154 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: ORACLE Study - Outcomes With Novel Combination Therapies in Non-Clear Cell RCC
FEATURING
Deepak Kilari
- 16 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: INSPIRE Trial - Nivolumab and Ipilimumab in Molecularly Selected mCRPC Patients
FEATURING
Niven Mehra
- 126 views
- October 1, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial
FEATURING
Bradley McGregor
- 64 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Multi-Gene Copy Number Variation Risk-Score for Predicting Survival and Therapy Response in Treatment-Naïve mCRPC
FEATURING
Manish Kohli
- 17 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EMBARK Study Post-Hoc Analysis By Age - Enzalutamide +/- Leuprolide in Patients With High-Risk Biochemically Recurrent Prostate Cancer
FEATURING
Neal Shore
- 63 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RAPSON Study - Radium223-Docetaxel vs. Docetaxel-Radium223 Sequence in mCRPC with Prospective Biomarker Evaluation
FEATURING
Vincenza Conteduca
- 23 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT
FEATURING
Hoda Abdel-Aty
- 104 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PEACE-1 Trial - Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer
FEATURING
Cedric Pobel
- 27 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: VOLGA Trial - ctDNA Clearance in Cisplatin-Ineligible MIBC With Durvalumab + Tremelimumab + Enfortumab Vedotin
FEATURING
Alexandra Drakaki
- 54 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SOGUG-AUREA Study - Split-Dose Cisplatin and Atezolizumab in Cisplatin-Ineligible Urothelial Carcinoma
FEATURING
Guillermo de Velasco
- 58 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predictive Tumor Suppressor Gene Signature for Early Progression in mHSPC
FEATURING
Marta Garcia De Herreros
- 24 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC - Ph3 CheckMate 67T
FEATURING
Laurence Albiges
- 118 views
- September 19, 2024
- 1
GYN
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New Therapeutic Approaches in Gynecologic Cancers
FEATURING
Susana Banerjee
- 91 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges
FEATURING
Mansoor Raza Mirza
- 375 views
- September 20, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease
FEATURING
Domenica Lorusso
- 205 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Advanced Ovarian Cancer - PRIMA Trial
FEATURING
Bradley J. Monk
- 509 views
- September 19, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial
FEATURING
Bradley J. Monk
- 270 views
- September 19, 2024
- 1
ecancer
ESMO 2024 Insights: Novel ADC TORL-1-23 in Heavily-Pretreated Ovarian, Endometrial, and Testicular Cancers
FEATURING
Gottfried Konecny
- 47 views
- October 14, 2024
ecancer
ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian Cancer Treated With Niraparib for 1L Maintenance
FEATURING
Antonio González-Martín
- 151 views
- October 14, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Dose Optimization of Gotistobart + Pembro in Platinum-Resistant Ovarian Cancer - PRESERVE-004/GOG-3081 Study
FEATURING
Joyce Barlin
- 48 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HER2 Expression and Its Relationship to HRD Status and Biomarkers in Ovarian Cancer
FEATURING
Dahye Lee
- 69 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinum-Sensitive Ovarian Cancer With High FRα - PICCOLO Trial Results
FEATURING
Angeles Secord
- 128 views
- October 1, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Stereotactic RT Alone or Followed by Niraparib for OMD or OPD in Ovarian Cancer Following PARPi Therapy - SOPRANO Trial
FEATURING
Susana Banerjee
- 59 views
- October 7, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Risk Factors for Recurrence and Prognostic Subgroups in Stage I Uterine Leiomyosarcomas - Insights From the Daydream Study
FEATURING
Alejandro Gallego
- 34 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Induction Chemo Followed by CRT in Advanced Cervical Cancer - QoL Outcomes From GCIG INTERLACE
FEATURING
Gemma Eminowicz
- 76 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant Chemo +/- RT in Pts With Newly Diagnosed, High-Risk Endometrial Cancer From ENGOT-EN11/GOG-3053/KEYNOTE-B21
FEATURING
Brian Slomovitz
- 233 views
- September 26, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS From the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo With Standard Cx + Bev in Ovarian Cancer Patients With Platinum-Sensitive Relapse
FEATURING
Jean-Emmanuel Kurtz
- 32 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Clinical and Molecular Predictors of Outcome in Patients With Tubo-Ovarian High-Grade Serous Carcinoma and Exceptional Survival
FEATURING
Tibor A. Zwimpfer
- 71 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: OS Results for Pembro + CRT for High-Risk Locally Advanced Cervical Cancer - ENGOT-cx11/GOG-3047/KEYNOTE-A18
FEATURING
Domenica Lorusso
- 185 views
- September 23, 2024
- 2
Lung
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Comparing Standard 75mg/m² and Fixed 50mg Cisplatin Doses in NSCLC Treatment Response and Toxicity
FEATURING
Maher Salamoon
- 28 views
- December 3, 2024
- 1
ecancer
ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON, REZILIENT1, LAURA, and SKIPPirr
- 260 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Discussing Key Studies on the Use of Zipalertinib, Zidesamtinib, and PM8002/BNT327 With CT in NSCLC
FEATURING
Joop Langen
- 77 views
- October 7, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients With Bone Metastases
FEATURING
Robbe Van den Begin
- 462 views
- September 26, 2024
- 7
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-Deruxtecan Related ILD - A Real-World Experience
FEATURING
Kelsey Natsuhara
- 853 views
- October 14, 2024
- 4
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CCTG BR.31 - Adjuvant Durvalumab in Completely Resected NSCLC
FEATURING
Glenwood Goss
- 19 views
- October 21, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: LBA51 DUART Trial - ctDNA Dynamics and Treatment Responses in CT-Ineligible Stage III NSCLC
FEATURING
Andrea Filippi
- 11 views
- October 11, 2024
ecancer
ESMO 2024 Insights: PIONeeR Trial - IO Resistance Pathways Investigated to Tailor Combination Advanced NSCLC Therapy
FEATURING
Pascale Tomasini
- 28 views
- October 11, 2024
ecancer
ESMO 2024 Insights: Canadian Cancer Trials Group BR.31 Study - Adjuvant Durvalumab After Complete Tumor Resection & Optional Chemo in Early Stage (IB-IIIA) NSCLC
FEATURING
Glenwood Goss
- 24 views
- October 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EP0031 - Next-Generation RET Inhibitor Correlating Molecular and Clinical Responses in RET-Altered Solid Tumors
FEATURING
Elena Garralda
- 41 views
- October 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: ARROS-1 Study - Zidesamtinib in Advanced ROS1 Fusion-Positive NSCLC and Other Solid Tumors
FEATURING
Benjamin Besse
- 38 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Acquired Resistance to 1L Amivantamab + Lazertinib vs. Osimertinib in EGFR-Mutant aNSCLC - Early MARIPOSA Study Analysis
FEATURING
Benjamin Besse
- 163 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: IBI354 - Anti-HER2 ADC in Advanced Solid Tumors and Breast Cancer
FEATURING
Christina Teng
- 76 views
- October 1, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RELATIVITY-104 Study - Nivo + Relatlimab With Platinum-Doublet Chemo vs. Nivo + Platinum-Doublet Chemo as 1L Treatment for Stage IV or Recurrent NSCLC
FEATURING
Nicolas Girard
- 139 views
- September 18, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Emerging Molecular Targets in Thymic Epithelial Tumors
FEATURING
Anja Roden
- 46 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Current and Future Use of EGFR-Targeted Agents in Lung Cancer
FEATURING
Pilar Garrido
- 155 views
- September 26, 2024
- 1
Head & Neck
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CT Followed by CRT for Elderly Patients With Advanced Laryngeal Cancer - Evading Surgical Intervention
FEATURING
Maher Salamoon
- 23 views
- December 3, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: H&N Cancer Brief Overview and KEYNOTE-048 Trial Results
FEATURING
Coral Olazagasti
- 19 views
- November 29, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Eftilagimod Alpha + Pembro vs. Pembro in 1L Recurrent/Metastatic HNSCC - TACTI-003 Trial Results Overview
FEATURING
Coral Olazagasti
- 15 views
- November 29, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: ADT vs. Chemo in Recurrent/Metastatic AR-Expressing Salivary Gland Cancer
FEATURING
Coral Olazagasti
- 26 views
- November 29, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Take Home Messages
FEATURING
Paolo Bossi
- 365 views
- October 8, 2024
- 6
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Highlights
FEATURING
Nabil Saba
- 337 views
- September 23, 2024
- 5
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: 3-Weekly vs. Weekly Cisplatin in High-Risk HNSCC Post-Op CRT - Final Results of JCOG1008
FEATURING
Makoto Tahara
- 220 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Avelumab-Cetuximab-RT vs. SoC in Locally Advanced HNSCC - Final Analysis From the REACH Trial
FEATURING
Makoto Tahara
- 156 views
- September 20, 2024
ecancer
ESMO 2024 Insights: EA3163 Trial - Chemo Followed by Surgery & PORT vs. Surgery & PORT for Organ Preservation of T3 & T4a (Selected T4b) Sinonasal Squamous Cell Carcinoma
FEATURING
Nabil Saba
- 24 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACTI-003 - Eftilagimod Alpha + Pembro vs. Pembro Alone in 1L Recurrent/Metastatic HNSCC
FEATURING
Hisham Mehanna
- 20 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Sequential vs. Induction CT With Concurrent CRT for Locoregionally Advanced Nasopharyngeal Carcinoma
FEATURING
Hisham Mehanna
- 37 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Neoadjuvant Chemo Followed by Surgery & Post-Operative RT vs. Surgery & Post-Operative RT for Organ Preservation of T3 & T4a Nasal and Paranasal Sinus SCC
FEATURING
Nabil Saba
- 62 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: GORTEC 2017-01 REACH Trial - Avelumab-Cetuximab-RT vs. Standards of Care in Patients With Locally Advanced SCC of Head & Neck
FEATURING
Yungan Tao
- 64 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Setanaxib + Pembro in Recurrent or Metastatic HNSCC
FEATURING
Makoto Tahara
- 91 views
- September 20, 2024
Skin
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Long-Term Survival Outcomes in Advanced Melanoma - Insights From CheckMate 067, KEYNOTE-006, and ImmunoCobiVem Trials
FEATURING
Jessica Hassel
- 34 views
- November 6, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Follow-Up Brain Imaging in Melanoma Patients With Brain Metastasis After ICI
FEATURING
Imren Ozdamar
- 15 views
- November 4, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Neoadjuvant Immunotherapy as the Future of Melanoma Treatment - Identifying Patients Who Need Surgery
FEATURING
Alexander van Akkooi
- 63 views
- October 9, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials
FEATURING
Douglas Johnson
- 195 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Metastatic Melanoma Highlights
FEATURING
Christian Blank
- 211 views
- September 25, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Survival Impact of Adjuvant Treatment in Stage III Melanoma
FEATURING
Hildur Helgadottir
- 113 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Distant Metastasis-Free Survival in Neoadjuvant vs. Adjuvant Nivo for Stage III Melanoma - The NADINA Trial
FEATURING
Alexander van Akkooi
- 18 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Biomarker Analysis and Outcomes in Neoadjuvant Nivo + Relatlimab for Resectable Melanoma
FEATURING
Liz Burton
- 26 views
- October 17, 2024
ecancer
ESMO 2024 Insights: NADINA Trial - Neoadjuvant Ipi Added to Nivo in Resectable Advanced Melanoma
FEATURING
Minke Lucas
- 26 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Sentinel Node (SN) Positive Melanoma With Minimal SN Tumor Burden - Primary Results of the EORTC 1208 Minitub Trial
FEATURING
Alexander van Akkooi
- 30 views
- October 9, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: KEYNOTE-716 - Final Analysis of Distant Metastasis-Free Survival With Adjuvant Pembro vs. Placebo in Resected Stage IIB/IIC Melanoma
FEATURING
Jason Luke
- 27 views
- October 7, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predicting the Outcomes of Advanced Cutaneous Melanoma Cases Following Discontinuation of Immune Checkpoint Inhibition
FEATURING
Ka-Won Noh,
Oana Diana Persa
- 70 views
- October 3, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CFT1946, a Novel BRAF V600X Degrader, in Preliminary Results in BRAF V600 Mutant Solid Tumors
FEATURING
Maria Vieito
- 26 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nivo + Ipi ± ASTX727 in Anti-PD-1 Resistant Metastatic Melanoma - NIBIT-ML1 Ph2 Study
FEATURING
Anna Maria Di Giacomo
- 76 views
- September 20, 2024
- 2
Hematologic Oncology
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in the Treatment of MCL
FEATURING
Georg Hess
- 240 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 469 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: IDH Mutated Cholangiocarcinoma - Diagnostic and Treatment Paradigm
FEATURING
Teresa Macarulla Mercade
- 41 views
- September 30, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Primary CNS Lymphoma - Updated ESMO and EHA Guidelines
FEATURING
Andres Ferreri
- 99 views
- September 30, 2024
- 1
Sarcoma
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights of Important Trials in Sarcoma
FEATURING
Robin Jones
- 213 views
- October 9, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: MOTION Trial - Updated Efficacy & Safety of Vimseltinib in Patients With Tenosynovial Giant Cell Tumor
FEATURING
Hans Gelderblom
- 28 views
- September 25, 2024